RxDoctor Payments Data

Yamileth Wu-Gerrard

Nurse Practitioner · Newark, DENPI 1215977707

Payments from drug & device makers

$1,839in general payments, 2019–2025

Across 65 payments — averaging $28.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$514
  • Fresenius USA Marketing, Inc.$346
  • Akebia Therapeutics Inc$178
  • AstraZeneca$162
  • Mallinckrodt Hospital Products Inc.$141
  • Amgen$134
  • plus $364 from 9 others

What the payments were for

  • Food & beverage$1,76396%
  • Education$764%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,839 in reported general payments places this provider in the 85th percentile of 487 nurse practitioner providers in Delaware.

See all nurse practitioner providers in Delaware

Medicare billing

Part B allowed, 2024
$17,740
Medicare patients
108
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide12$32,461
Sevelamer Carbonate19$7,780
LokelmaSodium Zirconium Cyclosilicate12$5,019
Metoprolol Succinate13$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$346$32,46112 claims
AstraZenecaLokelma$162$5,01912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 487 nurse practitioner providers in Delaware.

Other nurse practitioner in Newark

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →